Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Arecor Therape (AREC) Share Price

Intraday
Historical

Price	48.00p on 27-03-2025 at 17:30:01
Change	0.00p 0%
Buy	50.00p
Sell	46.00p
Buy / Sell AREC Shares

Last Trade:	Sell 10,597.00 at 47.144p
Day's Volume:	25,790
Last Close:	48.00p
Open:	48.00p
ISIN:	GB00BMWLM973

Day's Range	48.00p - 48.00p
52wk Range:	48.00p - 170.00p
Market Capitalisation:	£18m
VWAP:	47.31271p
Shares in Issue:	38m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Arecor Therape (AREC) Latest Trades
Sell*	10,597	47.144p	Ordinary	12:38:35 - 27-Mar-25
Sell*	10,567	47.277p	Ordinary	12:36:11 - 27-Mar-25
Sell*	126	47.45p	Ordinary	10:53:16 - 27-Mar-25
Sell*	4,500	47.79p	Ordinary	09:31:21 - 27-Mar-25
Sell*	850	47.945p	Ordinary	16:06:34 - 26-Mar-25
Sell*	1,000	48.00p	Ordinary	15:05:04 - 26-Mar-25
Sell*	1,000	48.00p	Ordinary	15:04:36 - 26-Mar-25
Unknown*	37,387	45.50p	Negotiated Trade	14:55:30 - 26-Mar-25
Sell*	5,660	50.00p	Ordinary	11:45:46 - 26-Mar-25
Sell*	1,000	50.00p	Ordinary	11:17:02 - 26-Mar-25

See more Arecor Therape trades

Arecor Therape (AREC) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
27th Mar 2025 (Thu)	48.00	48.00	48.00	48.00	25,790
26th Mar 2025 (Wed)	51.50	51.50	48.00	48.00	53,879
25th Mar 2025 (Tue)	49.00	49.00	49.00	49.00	4,281
24th Mar 2025 (Mon)	49.00	49.00	49.00	49.00	2,882
21st Mar 2025 (Fri)	49.00	49.00	49.00	49.00	0
20th Mar 2025 (Thu)	49.00	49.00	49.00	49.00	123
19th Mar 2025 (Wed)	49.50	49.50	49.00	49.00	11
18th Mar 2025 (Tue)	49.50	49.50	49.50	49.50	7,918
17th Mar 2025 (Mon)	49.50	49.50	49.50	49.50	15,082
14th Mar 2025 (Fri)	50.50	50.50	49.00	49.50	44,675
13th Mar 2025 (Thu)	50.50	51.00	50.50	50.50	32,204
12th Mar 2025 (Wed)	50.50	53.00	50.50	50.50	1,375
11th Mar 2025 (Tue)	50.50	50.50	50.50	50.50	845
10th Mar 2025 (Mon)	50.50	50.50	50.50	50.50	0
7th Mar 2025 (Fri)	50.50	50.50	50.50	50.50	0
6th Mar 2025 (Thu)	50.50	50.50	50.50	50.50	1,998
5th Mar 2025 (Wed)	50.50	50.50	48.00	50.50	3,614
4th Mar 2025 (Tue)	50.50	50.50	50.50	50.50	14,178
3rd Mar 2025 (Mon)	50.00	48.00	48.00	48.00	194,054
28th Feb 2025 (Fri)	50.00	50.00	50.00	50.00	38,984

See more Arecor Therape price history

Date	Source	Headline
Arecor Therape (AREC) Regulatory News
26th Mar 2025 7:00 am	RNS	Collaboration with global pharmaceutical partner
12th Mar 2025 7:00 am	RNS	Arecor partnership with biopharmaceutical company
3rd Feb 2025 7:00 am	RNS	Arecor Full Year 2024 Trading Update
10th Jan 2025 7:45 am	RNS	Orderly Cessation of Tetris Pharma Operations
9th Jan 2025 7:00 am	RNS	Change of Nominated Advisor and Joint Broker
30th Dec 2024 7:00 am	RNS	Arecor Signs Exclusive Licensing Agreement
2nd Dec 2024 7:00 am	RNS	Grant of Options and PDMR Dealing
18th Nov 2024 7:00 am	RNS	Arecor Appoints Interim Chief Financial Officer
26th Sep 2024 7:00 am	RNS	Interim Results for six months ended 30 June 2024
19th Sep 2024 3:17 pm	RNS	Notice of Results

See more Arecor Therape regulatory news

Arecor Therape (AREC) Share News

Arecor Therapeutics strikes deal for development of peptide therapy

12th Mar 2025 15:34

(Alliance News) - Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed biopharmaceutical company to develop a novel formulation of peptide therapy. Read More

Arecor Therapeutics confident for the future as revenue rises

3rd Feb 2025 13:28

(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". Read More

IN BRIEF: Arecor Therapeutics shares tumble as plans Tetris wind-down

10th Jan 2025 21:21

Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces the orderly cessation of operations within the Tetris Pharma subsidiary, and a mutual agreement with Xeris BioPharma Holdings Inc to return the group's rights to medication Ogluo. Forms part of the group's strategic review. This concludes that rising supply chain costs and fixed selling prices have significantly reduced margins for Ogluo. In addition, the 2025 revenue outlook for non-Ogluo sales has been materially reduced in light of a partner losing a key NHS tender, materially reducing 2025 revenues for non-Ogluo products. The strategic decision to cease Tetris Pharma operations will enable the group to focus its efforts and resources on opportunities that offer "higher potential for value creation." Read More

IN BRIEF: Arecor Therapeutics signs new drug licensing agreement

30th Dec 2024 11:44

Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Signs licensing agreement for its AT351 liquid drug product with "a wholly owned subsidiary of one of the world's largest independent chemicals marketing companies". Arecor says it receives an undisclosed upfront payment and is eligible for development, regulatory, and commercial milestone payments and royalties on global sales. The licensee receives an exclusive worldwide license and is responsible for all development, regulatory and commercialisation activities. The licensee will pursue approval from the US Food & Drug Administration, with filing expected within three years. Read More

LONDON MARKET OPEN: European blue-chips decline in tepid early trade

30th Dec 2024 08:52

(Alliance News) - Stock prices in London registered a softer open on Monday, with barely a handful of the FTSE 100 in the green, in uninspiring trade as the year draws to a close. Read More

See more Arecor Therape news

FTSE 100 Latest

Value8,666.12

Change-23.47

Arecor Therape (AREC) Share Price

Login to your account